Sagittarius Life Science (3205) — Cash Flow-to-Debt Ratio
Sagittarius Life Science (3205) has a Cash Flow-to-Debt Ratio of -0.79x as of December 2025, meaning its operating cash flow of NT$-21.27 Million could theoretically repay -1% of its total liabilities (NT$26.91 Million) in one year. Explore long-term investment intensity of Sagittarius Life Science to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sagittarius Life Science Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Sagittarius Life Science across 11 annual periods. Also explore Sagittarius Life Science total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Sagittarius Life Science (2015–2025)
Year-by-year debt coverage analysis for Sagittarius Life Science. For market capitalisation and broader financial context, see 3205 company net worth.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.34x | NT$-36.05 Million | NT$26.91 Million | ▼ -201.4% |
| 2024 | -0.44x | NT$-44.48 Million | NT$100.07 Million | ▲ +11.7% |
| 2023 | -0.50x | NT$-69.37 Million | NT$137.82 Million | ▼ -17.7% |
| 2022 | -0.43x | NT$-52.89 Million | NT$123.70 Million | ▼ -111.0% |
| 2021 | -0.20x | NT$-29.18 Million | NT$144.03 Million | ▲ +50.4% |
| 2020 | -0.41x | NT$-62.24 Million | NT$152.36 Million | ▲ +46.4% |
| 2019 | -0.76x | NT$-104.50 Million | NT$137.09 Million | ▼ -27.0% |
| 2018 | -0.60x | NT$-57.86 Million | NT$96.38 Million | ▼ -150.2% |
| 2017 | -0.24x | NT$-23.31 Million | NT$97.16 Million | ▼ -113.4% |
| 2016 | 1.80x | NT$360.37 Million | NT$200.51 Million | ▲ +215.0% |
| 2015 | 0.57x | NT$237.94 Million | NT$416.95 Million | — |